NewAmsterdam Pharma Company N.V.
NAMSW
NASDAQ Capital Market18.72
USD
+0.52
- -
CIK
0001936258
ISIN
NL00150012K9
Return %
Stock
S&P500
1Y
64.21
19.01
3Y
808.74
65.48
5Y
1,753.47
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Michael Harvey Davidson Facp.
- Full Time Employees
- 100
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Gooimeer 2-35 Naarden NH Netherlands 1411 DC
- IPO Date
- Feb 10, 2021
- CIK
- 0001936258
- Website
- newamsterdampharma.com
- Similar Companies
- Business
- NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for serious brain and neurodegenerative diseases. Its core product pipeline includes therapeutic candidates designed around vascular and neuro-inflammatory mechanisms for conditions such as cerebral cavernous malformation (CCM) and Parkinson’s disease. The company develops proprietary formulations aimed at modulating neurovascular and inflammatory pathways to address significant unmet medical needs within neurology. NewAmsterdam Pharma operates primarily through its research, development, and clinical trial activities based in the United States and European markets, targeting healthcare providers and patients affected by neurological disorders. The company was founded in 2019 and is headquartered in the Netherlands. In the past 1-2 years, NewAmsterdam Pharma has made strategic progress including advancing its lead clinical candidates through pivotal trial phases, initiating new collaborative partnerships to bolster research and development efforts, and expanding its operational footprint to support clinical and commercial activities. The company also completed a successful funding round to accelerate product development and pipeline expansion. These developments reflect NewAmsterdam Pharma's commitment to innovative neurology therapeutics and its evolving strategic focus on rapidly advancing products toward regulatory approval and commercialization. NewAmsterdam Pharma’s business segments encompass biotechnology research and product development, clinical drug manufacturing, and licensing of therapeutic candidates. Its target market includes patients with critical neurovascular and neurodegenerative conditions, healthcare institutions, and pharmaceutical partners. The company functions with a lean corporate structure while maintaining collaborations globally to enhance scientific and commercial capacity. It operates independently as a publicly traded entity under the ticker NAMSW.
NewAmsterdam Pharma (NASDAQ:NAMSW) Shares Down 19.2% – Time to Sell?
NewAmsterdam Pharma (NASDAQ:NAMSW) Trading 0.2% Higher – Still a Buy?